you and David, everyone. Thank today. you, afternoon for joining Thank us good
the by combat selfless and care these responders affected unprecedented pandemic, go crisis. other applaud we health the this our their efforts families this to workers and the out to frontline times, hearts During for
committed is surgeons company, around a in their Establishment patients world As to Labs the and can. plastic helping health women's we our way whatever
moment have each a while take to local possible efficiently as time to time who response to operations like and our given employees, same our the of and keep the running their tirelessly thank working at I'd as current circumstances. smoothly help resources to efforts, support donated
In particular, our I health employees Costa spend our recovering face how shields sure several acknowledge patients the outlook. protected assembled as would who and at in elderly our major to like first other minutes few care and care impact Ministry have like the to workers local performance, for thousand Rica from the who but Health organizations from quarter and discussing to to expect of individuals. COVID-XX interested a illnesses I'm we I'd in at-risk just distributed you're
can XXXX. as much frame of remainder So we to the with information we'll you as provide help
adopt our brands to strength the and our were momentum by March still impacted measurably Even our first and Motiva continue We reflects over at higher our are of sales call. plastic the earnings to to towards This end last report period their surgeons of Labs illustrates COVID-XX, the we pleased record first Implants. another patients during and the the as product that ago quarter were $XX our Establishment guided XX% for $XX.X represented million range and market. million though year quarter quarter sales growth million $XX in
in procedures, breast countries expect as the at during enhancement Overall, and of procedures. in steep we to elective curtail decline see began QX March various speeds across were one non-essential strong, as to a would month sales medical began but activities different geographies, including
a some greatly albeit April, at did in in countries, procedures While most countries were rate. shut reduced down continue
now back online. seeing come number to begin are a We countries of
is those and to breast hospitals, surgeons. but those are performed that that procedures of at which more spread resuming enhancement COVID rates steps in in important private back by who control or took to not quickly. cross countries majority aggressive also countries and appears are are it of the that Procedures plastic owned are remember earliest controlled varying its It faced clinics coming often
reason, we other procedure For elective room would a more compete this that to procedures expect might you return time. see rapid than volumes operating with normal hospital-based for
in represents geographically As diverse revenue a more single our Brazil country than our XX countries. reminder XX% base over no is with for Except of sales sales.
makes to accurately each difficult extremely helps forecast also to diversity risk, normalcy. the While country return to as XXXX global path its on it sales spread has it own
forgo to have at For guidance this sales decided time. this reason, providing full year we
that we clearer, the We to as in able be guidance becomes are hopeful will year. the provide global later outlook
COVID-XX, sales impact QX be the global will impacted. negatively of Given
are beginning And improve of sequentially we revenue. QX geographies. to do we seeing evidence in and However reason this we believe conditions see in QX for certain will increases that
QX As we for canceled being rescheduled to half of it the year than think many about rather seeing that this note in we helpful being are balance this the of may year, procedures outright. second be
previous women This several breast believe consideration women deep take with to of research and through surgery. years a behavior true industry our breast made once been to and most to consistent augmentation that a proceed with surgery. take considering both period when very through headlines. seems This decision many are negative A determined recessions also they undergone when we their significant augmentation the have exhaustively research has suggests follow has
health resilient to is unique testament very procedure been of unprecedented very making patients our invest in important strongly is choose is long-term of and it. safety how this Motiva resonating has with themselves. to much this and a the this women to a who decision have In profile to commitment industry women's Our time
play out again. once We this seeing determination are
patients decided before year-to-year to now share the gains. of In Brazil, the which we data Even for growth example, enhancement global that until procedures. have and Implants Motiva their our recovery, with uncertainty XX% fundamentals of not portfolio, around robust of of market our shows the pandemic strength postpone cancel that product speed breast business up the in the and in resulted remain confident our has chose
and and will turbulent have experience reconstruction Our just has breast in this we we Executive team before. as decades navigate aesthetics of time
had COVID-XX appear rate as to breast of does have media searches on relatively beginning much and seeing. are their impact by web evidenced social steady research activity augmentation women not who are the we
staff. women for There offering protocols face-to-face consultations and is pickup incorporating patients adapting a online slower COVID-specific and and scheduling by in consultations surgeons new plastic safety are their office more
have We seen large converted training online seminars and webinars in-person have programs MotivaEdge in attendance. to our quickly and increases
participants. least and over of webinars Some had nearly routinely several our of have hundred registrants X,XXX events all attract these at
are message how And can in science they practices this the their to innovation and presentations around about line time tissue much learn about Plastic think very improve with taking of innovations breast and Labs' of is this in Establishment surgeons their field. management.
taken steps our further and Despite uncertain to to company prepare and recovery us have market the position times decisive share long-term we our weather for bullishness business, early breast and gains. implant about these strong a
planned management these provide we expenses spending, actions scaling travel by reduced eliminating few in Specifically, reducing moments. our lowering Renee greater unnecessary manufacturing compensation. and by approximately and temporarily back detail will operations, headcount, XX% employee about XXXX have our a non-essential discretionary
are we expenses, investing areas. also certain reducing in While strategic
reducing manufacturing our well excellence program For waste. global business enhance from and productivity to organization expanding entire efficiencies our example, to as we are as
including program Since generated in cost over XXXX. in $X.X savings $X million million has XXXX, this
investing will in our in XXXX, new the footprint. we With resources normal be more digital
Our digital patients our leverage aesthetic media and digital team breast procedures. provide focused valuable social initiatives into is strengthen channels marketing on seeking presence to that other insight
them plans to to the with in advancing also who aesthetic restarting of support our safety Motiva. interested are patients are in practices their We by plastic countries improved linking and surgeons outcomes select
success complex believe will quickly the in is of that remains agile and pandemic. entrepreneurial that I these result that Establishment has and dynamic from the even environments. can uncertainty an Labs well-positioned company for even as the an actions navigate growth resulted adapt continued we COVID stronger combination that organization and to
and invest medical more new being by critical devices U.S. are continuing new Labs centers has understandably smooth our have focus on as in most currently needs. COVID-XX entering markets. worldwide comprehensive their Clinical studied advanced impacted in portfolio Establishment we the by to of future trials been implants and products developing energies hospitals of
activate IRB the reconstruction pandemic could to of pivotal timeline. our delayed cohort our trial, in six Motiva the continue approvals, enrollment Although which to has secure we and sites months add trial at least
already follow-up in As and year our was know, you phase. cohorts last the completed aesthetic in enrollment are presently we
to sites in are We of FDA's protocol. as are their monitoring guidance already consultations several with the modifying follow-up our our patients COVID-XX of U.S. conducting plans and and virtual part patient according follow-up the
As comprised of XX% of is breast U.S. implant a reminder, procedures. aesthetic the roughly market
CE Europe compelling for to available Mark Flora our We proprietary will We an goal in year. continue of development important believe of still We Flora a of expander. a advantages product towards approval expect begin and tissue activities and to offer be product Flora to features portfolio. part FDA receive our work receiving for the currently this market
to last results the surgeries. we the now slowed Asia pleased although additional December cases and very our breast augmentation has Motiva began Turning proof-of-concept in minimally initiative we Mia pace with invasive are COVID-XX of
patient are and expand Surgeon our positive additional working countries. and has to series we been initial feedback patient in
our of biocompatibility in addressable year We grow are breast the long-term breast on Surface. our the this highly a aesthetics respected believe market has minimally the total we groundbreaking introduction SmoothSilk publication Later continue strategy. a of for that procedure journal invasive study to the of contribute to potential proprietary to a expecting the augmentation growth scientific and
unique market combined to and our market with This in growing feedback, are continued publications evidence the patient like and adoption of on date surgeon profile paper to Publications drive will for add reasons Implants. key peer Motiva and body gains. experience, help share this, should success of the positive reviewed safety
Turning aspects that We to this issuance implants. innovative surface Motiva the the safety exceptional the the a a and other profile company patent advantage. our proprietary Motiva protects announced one with of the quarter, of strong of technology U.S. competitive technology of we of believe provides key is our developments, during
portfolio. developing protect improve robust patient to outcomes continue We innovations to dedicate innovations will those that a with and resources IP
Rosalyn Finally, we are will energy implant effort. clinical XX d'Incelli has than team experience leadership in affairs our will for our more who on who to focus U.S. years initially pleased Implants. industry and to IDE her medical our Rosalyn Motiva the lead welcome breast of
a implants and who market, large of women results. enhancement XX% bringing our round seek and opportunity look At breast represents U.S. company approximately we outstanding global growth Motiva our the aesthetic innovative forward for to to the ergonomic
the the call that, With turn Renee? detail. Renee like to discuss to over I'd to in financials
